Leo Pharma and Astrazeneca keep future plans tight for tralokinumab
Neither Leo Pharma nor Astrazeneca wants to reveal the future plans for tralokinumab, which has just been approved as an atopic eczema treatment in the US. The drug has blockbuster potential in the approved indication, and while other indications might be considered, Astrazeneca retains the rights for several lucrative indications.
Jörg Möller, head of global research and development at Leo Pharma, doesn't have a lot to say when it comes to Leo Pharma's hopes for tralokinumab besides atopic eczema
by ULRICH QUISTGAARD, translated by daniel pedersen
The US approval of Leo Pharma's eczema drug, tralokinumab, has been a popular topic at the Danish dermatology firm, which has clear blockbuster expectations for the treatment.
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
With increasing competition in the hearing aid market, Jyske Bank analyst Janne Vincent Kjær does not expect Demant to continue its strong momentum into 2024.
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
With increasing competition in the hearing aid market, Jyske Bank analyst Janne Vincent Kjær does not expect Demant to continue its strong momentum into 2024.